Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions

Moghimi, Seyed Moein; Haroon, Hajira B.; Yaghmur, Anan; Hunter, A. Christy; Papini, Emanuele; Farhangrazi, Z. Shadi; Simberg, Dmitri; Trohopoulos, Panagiotis N.

doi:10.1016/j.jconrel.2023.02.022

Cited by 16 publications

(11 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth mentioning that Brucella can efficiently colonize cells of the monocyte/macrophage lineage and replicate in high numbers in the liver and spleen. , Phagocytic cells internalize particles more efficiently than other host cells, which results in the accumulation of nanoparticles in the mononuclear phagocyte system (MPS) organs, such as the liver and spleen . This accumulation becomes advantageous for targeting intracellular infections that affect the MPS, such as brucellosis . Therefore, nanoparticles not only improve the efficacy of current treatments but also reduce adverse effects and mitigate drug resistance, common issues in this type of infection.…”

Section: Resultsmentioning

confidence: 99%

Enhancing Therapeutic Efficacy against Brucella canis Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles

Hernández-Giottonini,

Arellano-Reynoso,

Rodríguez-Córdova

et al. 2023

ACS Omega

View full text Add to dashboard Cite

The in vivo efficacy of rifampicin encapsulated in poly(lactic- co -glycolic acid) (PLGA) nanoparticles was evaluated for the treatment of BALB/c mice experimentally infected with Brucella canis . The PLGA nanoparticles loaded with rifampicin (RNP) were prepared using the single emulsification-solvent evaporation technique, resulting in nanoparticles with a hydrodynamic diameter of 138 ± 6 nm. The zeta potential and polydispersity index values indicated that the system was relatively stable with a narrow size distribution. The release of rifampicin from the nanoparticles was studied in phosphate buffer at pH 7.4 and 37 °C. The release profile showed an initial burst phase, followed by a slower release stage attributed to nanoparticle degradation and relaxation, which continued for approximately 30 days until complete drug release. A combined model of rifampicin release, accounting for both the initial burst and the degradation–relaxation of the nanoparticles, effectively described the experimental data. The efficacy of RNP was studied in vivo ; infected mice were treated with free rifampicin at concentrations of 2 mg per kilogram of mice per day (C1) and 4 mg per kilogram of mice per day (C2), as well as equivalent doses of RNP. Administration of four doses of the nanoparticles significantly reduced the B. canis load in the spleen of infected BALB/c mice. RNP demonstrated superior effectiveness compared to the free drug in the spleen, achieving reductions of 85.4 and 49.4%, respectively, when using C1 and 93.3 and 61.8%, respectively, when using C2. These results highlight the improved efficacy of the antibiotic when delivered through nanoparticles in experimentally infected mice. Therefore, the RNP holds promise as a potential alternative for the treatment of B. canis .

show abstract

Section: Resultsmentioning

confidence: 99%

Enhancing Therapeutic Efficacy against Brucella canis Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles

Hernández-Giottonini,

Arellano-Reynoso,

Rodríguez-Córdova

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Using a Fischers exact test, we found that the serum-coated PS100 particles were functionally enriched for proteins involved in the coagulation and complement cascade, while no other particle had a functional enrichment in the differentially abundant proteins. The coagulation and complement cascade has been intensively studied in the context of nanomedicine, and the presence of these proteins was found to increase particle phagocytosis of liposomes and PMMA nanoplastics [ 68 , 69 ]. The complement proteins found on serum-coated PS100 included proteins with a known role in phagocytosis or that have previously been related to nanoparticle uptake, such as plasminogen [ 70 , 71 ], complement factor C3 [ 69 ], complement factor H [ 68 ], coagulation factor XIII A [ 72 ], prothrombin [ 73 ], alpha-1-antitrypsin [ 73 ] and von Willebrand factor 74 .…”

Section: Discussionmentioning

confidence: 99%

The in vitro gastrointestinal digestion-associated protein corona of polystyrene nano- and microplastics increases their uptake by human THP-1-derived macrophages

Brouwer,

Porbahaie,

Boeren

et al. 2024

Part Fibre Toxicol

View full text Add to dashboard Cite

Background Micro- and nanoplastics (MNPs) represent one of the most widespread environmental pollutants of the twenty-first century to which all humans are orally exposed. Upon ingestion, MNPs pass harsh biochemical conditions within the gastrointestinal tract, causing a unique protein corona on the MNP surface. Little is known about the digestion-associated protein corona and its impact on the cellular uptake of MNPs. Here, we systematically studied the influence of gastrointestinal digestion on the cellular uptake of neutral and charged polystyrene MNPs using THP-1-derived macrophages. Results The protein corona composition was quantified using LC‒MS–MS-based proteomics, and the cellular uptake of MNPs was determined using flow cytometry and confocal microscopy. Gastrointestinal digestion resulted in a distinct protein corona on MNPs that was retained in serum-containing cell culture medium. Digestion increased the uptake of uncharged MNPs below 500 nm by 4.0–6.1-fold but did not affect the uptake of larger sized or charged MNPs. Forty proteins showed a good correlation between protein abundance and MNP uptake, including coagulation factors, apolipoproteins and vitronectin. Conclusion This study provides quantitative data on the presence of gastrointestinal proteins on MNPs and relates this to cellular uptake, underpinning the need to include the protein corona in hazard assessment of MNPs. Graphical abstract

show abstract

“…This is attributed to their unique nanostructural versatility, the biocompatibility of their major lipid constituents (such as monounsaturated monoglycerides, diunsaturated monoglycerides, and omega-3 fatty acid monoglycerides), bioadhesive properties, and capability of loading and sustaining the release of amphiphilic, hydrophobic, and hydrophilic drugs [ 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 ]. Further, it is worth exploring the possible functionalization of hydrogels or polymeric matrices by embedding the corresponding nanoparticles of the inverse non-lamellar lyotropic liquid crystalline phases (particularly cubosomes and hexosomes), which are recently popular nano-self-assemblies in the development of nanocarriers for drug delivery applications [ 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 ], or through their immobilization for designing cubosome or hexosome coatings by employing chemical surface activation methods. The latter strategy is typically applied for immobilization of lamellar liquid crystalline nanoparticles (liposomes) and various soft and hard nanoparticles (such as silver nanoparticles) [ 49 , 70 , 72 , 105 ].…”

Section: Current Limitations and Future Directionsmentioning

confidence: 99%

Recent Advances in Antibacterial Coatings to Combat Orthopedic Implant-Associated Infections

Akay,

Yaghmur

2024

Molecules

Self Cite

View full text Add to dashboard Cite

Implant-associated infections (IAIs) represent a major health burden due to the complex structural features of biofilms and their inherent tolerance to antimicrobial agents and the immune system. Thus, the viable options to eradicate biofilms embedded on medical implants are surgical operations and long-term and repeated antibiotic courses. Recent years have witnessed a growing interest in the development of robust and reliable strategies for prevention and treatment of IAIs. In particular, it seems promising to develop materials with anti-biofouling and antibacterial properties for combating IAIs on implants. In this contribution, we exclusively focus on recent advances in the development of modified and functionalized implant surfaces for inhibiting bacterial attachment and eventually biofilm formation on orthopedic implants. Further, we highlight recent progress in the development of antibacterial coatings (including self-assembled nanocoatings) for preventing biofilm formation on orthopedic implants. Among the recently introduced approaches for development of efficient and durable antibacterial coatings, we focus on the use of safe and biocompatible materials with excellent antibacterial activities for local delivery of combinatorial antimicrobial agents for preventing and treating IAIs and overcoming antimicrobial resistance.

show abstract

Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions

Cited by 16 publications

References 152 publications

Enhancing Therapeutic Efficacy against Brucella canis Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles

Enhancing Therapeutic Efficacy against Brucella canis Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles

The in vitro gastrointestinal digestion-associated protein corona of polystyrene nano- and microplastics increases their uptake by human THP-1-derived macrophages

Recent Advances in Antibacterial Coatings to Combat Orthopedic Implant-Associated Infections

Contact Info

Product

Resources

About